Circumvent is developing medicines for rare, genetically defined forms of neurodegenerative disease. We have a lead program that is in IND-enabling studies for CLN1 Disease, which due to a well established natural history and defined patient population, provides a quick path to a pivotal trial and registration/market. The active component of the drug that Circumvent is developing has been exposed to 1000s of patients and has a well defined safety profile. In addition, Circumvent is utilizing key insights derived from the biology of rare, genetically defined forms of neurodegenerative disease to identify key nodes driving disease progression in sporadic, complex forms of disease such as Alzheimer’s, Huntington’s, and Parkinson’s. Circumvent has been able to utilize these key insights to develop several earlier stage program including targets in autophagy and cellular homeostasis.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):